Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae109 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Laura-Sophie Landwehr und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, 97080 Würzburg, Germany. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Research Foundation.
Abstract (Originalsprache)
Context
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with poor prognosis in advanced stages. While therapies targeting the checkpoint molecules programmed cell death 1 (PD-1), its ligand PD-L1, and the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have revolutionized treatment in many cancers, the results in ACCs were heterogeneous.
Objective
Their expression in ACC has not been systematically studied and might explain the variable response to immune checkpoint inhibitors.
Methods
The expression of PD-1, PD-L1 and CTLA-4 was examined in 162 tumor samples from 122 patients with ACC by immunohistochemistry (threshold of >1%) and correlated with tumoral T lymphocyte infiltration and clinical endpoints. Finally, univariate and multivariate analyses of progression-free and overall survival were performed.
Results
PD-1 and PD-L1 were expressed in 26.5% and 24.7% of samples, respectively, with low expression in most tumor samples (median positive cells: 2.1% and 21.7%). In contrast, CTLA-4 expression was observed in 52.5% of ACC with a median of 38.4% positive cells. Positive PD-1 expression was associated with longer progression-free survival (HR 0.50, 95% CI 0.25-0.98, P = .04) even after considering prognostic factors. In contrast, PD-L1 and CTLA-4 did not correlate with clinical outcome. Additionally, PD-1 and PD-L1 expression correlated significantly with the amount of CD3+, CD4+, FoxP3+, and CD8+ T cells.
Conclusion
The heterogeneous expression of PD1, PD-L1, and CTLA-4 in this large series of well-annotated ACC samples might explain the heterogeneous results of the immunotherapies in advanced ACC. In addition, PD-1 expression is a strong prognostic biomarker that can easily be applied in routine clinical care and histopathological assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, 97080 Würzburg, Germany.
- Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany.
- Institute GReD (Genetics, Reproduction and Development), University Clermont Auvergne, 63001 Clermont-Ferrand, France.
- Comprehensive Cancer Center Mainfranken, University of Würzburg, 97080 Würzburg, Germany.
- Department of Medicine IV, LMU University Hospital, LMU Munich, 80336 München, Germany.
- Clinical Chemistry and Laboratory Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
ORCID-Profile: Laura-Sophie Landwehr, Barbara Altieri, Hanna Remde, Julie Olabe, Silviu Sbiera, Matthias Kroiss, Martin Fassnacht
Förderung
- German Research Foundation
Zitieren
APA
Landwehr, L. S., Altieri, B., Sbiera, I., Remde, H., Kircher, S., Olabe, J., Sbiera, S., Kroiss, M., & Fassnacht, M. (2024). Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae109
Vancouver
Landwehr LS, Altieri B, Sbiera I, Remde H, Kircher S, Olabe J, et al. Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae109
BibTeX
@article{Landwehr2024,
author = {Landwehr, Laura-Sophie and Altieri, Barbara and Sbiera, Iuliu and Remde, Hanna and Kircher, Stefan and Olabe, Julie and Sbiera, Silviu and Kroiss, Matthias and Fassnacht, Martin},
title = {Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae109}
}
EUVIMED